Woodley Announces the Appointment of Vijay Manchha
Woodley Equipment Company, a leading specialist medical and laboratory equipment supplier to the Clinical Trials industry has welcomed a new member to their Team.
Woodley Equipment Company, a leading specialist medical and laboratory equipment supplier to the Clinical Trials industry has welcomed a new member to their Team. Vijay Manchha joins Woodley as the Business Development Manager for our Clinical Trials Division.
Vijay has comprehensive experience of the Clinical Trials Industry having previously worked for VWR and Fisher Scientific. In these roles Vijay was responsible for managing and developing varied accounts from Research and Academia to Pharmaceutical and Biotech clients.
Vijay joins Woodley at a time of expansion and growth and will be responsible for developing new business within the company’s existing global markets. Vijay will further strengthen Woodley’s ability to offer turnkey solutions to the Clinical Trials Industry.
Woodley Equipment has been a trusted supplier of equipment solutions to the Clinical Trials industry for over 20 years. Woodley is the supplier of choice to many of the largest companies in Clinical Research, as well as the partner of small and medium sized companies around the World.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
